Author

Gabriela Forestieri

Institute of Oncology Research

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Alberto J. ArribasiD· 2 shared Anastasios StathisiD· 2 shared Andrea RinaldiiD· 2 shared Chiara TarantelliiD· 2 shared Davide RossiiD· 2 shared Eleonora CannasiD· 2 shared Emanuele ZuccaiD· 2 shared Filippo SprianoiD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alberto J. ArribasORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas

Alberto J. Arribas, Eleonora Cannas, Giulio Sartori, Francesca Guidetti, Luciano Cascione, Sara Napoli, Gabriela Forestieri, Federica Fuzio, Emma Pesenti, Chiara Tarantelli, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, Alessio Bruscaggin, Andrea Rinaldi, , Francesco Bertoni

This study identifies IL-16 production as a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas, showing that targeting the IL-16/CD9 axis restores drug sensitivity.

Blood · May 29, 2026Peer-reviewedCancer Biology

Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models

Laura Barnabei, Alberto J. Arribas, Luciano Cascione, Gabriela Forestieri, Eleonora Cannas, Francesca Guidetti, Filippo Spriano, Elisa Civanelli, Chiara Tarantelli, Samuele Di Cristofano, Stefano Raniolo, Andrea Rinaldi, Anastasios Stathis, Davide Rossi, Emanuele Zucca, , Francesco Bertoni

This study shows that combining CXCR4 inhibitors with standard and targeted therapies improves anti-tumor effects in B-cell lymphoma models, especially in drug-resistant cases.

bioRxiv · Jul 10, 2025 · PreprintCancer Biology